Steven Davidsen

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Concepts & Ideas

Living Beings

Mice
Rats

Chemicals & Drugs

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Franklin Pamela H; Banfor Patricia N; Tapang Paul; Segreti Jason A; Widomski Deborah L; Larson Kelly J; Noonan William T; Gintant Gary A; Davidsen Steven K; Albert Daniel H; Fryer Ryan M; Cox Bryan F
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
Zhou Jianbiao; Bi Chonglei; Janakakumara Jasinghe V; Liu Shaw-Cheng; Chng Wee-Joo; Tay Kian-Ghee; Poon Lai-Fong; Xie Zhigang; Palaniyandi Senthilnathan; Yu Hanry; Glaser Keith B; Albert Daniel H; Davidsen Steven K; Chen Chien-Shing
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.
Hubbard Robert D; Bamaung Nwe Y; Fidanze Steve D; Erickson Scott A; Palazzo Fabio; Wilsbacher Julie L; Zhang Qian; Tucker Lora A; Hu Xiaoming; Kovar Peter; Osterling Donald J; Johnson Eric F; Bouska Jennifer; Wang Jieyi; Davidsen Steven K; Bell Randy L; Sheppard George S
Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Steven Davidsen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Franklin Pamela H; Banfor Patricia N; Tapang Paul; Segreti Jason A; Widomski Deborah L; Larson Kelly J; Noonan William T; Gintant Gary A; Davidsen Steven K; Albert Daniel H; Fryer Ryan M; Cox Bryan F
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
The Journal of pharmacology and experimental therapeutics 2009;329(3):928-37.
2009: Zhou Jianbiao; Bi Chonglei; Janakakumara Jasinghe V; Liu Shaw-Cheng; Chng Wee-Joo; Tay Kian-Ghee; Poon Lai-Fong; Xie Zhigang; Palaniyandi Senthilnathan; Yu Hanry; Glaser Keith B; Albert Daniel H; Davidsen Steven K; Chen Chien-Shing
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.
Blood 2009;113(17):4052-62.
2009: Hubbard Robert D; Bamaung Nwe Y; Fidanze Steve D; Erickson Scott A; Palazzo Fabio; Wilsbacher Julie L; Zhang Qian; Tucker Lora A; Hu Xiaoming; Kovar Peter; Osterling Donald J; Johnson Eric F; Bouska Jennifer; Wang Jieyi; Davidsen Steven K; Bell Randy L; Sheppard George S
Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.
Bioorganic & medicinal chemistry letters 2009;19(6):1718-21.
2009: Banfor Patricia N; Franklin Pamela A; Segreti Jason A; Widomski Deborah L; Davidsen Steven K; Albert Daniel H; Cox Bryan F; Fryer Ryan M; Gintant Gary A
ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.
Journal of cardiovascular pharmacology 2009;53(2):173-8.
2009: Pappano William N; Jung Paul M; Meulbroek Jonathan A; Wang Yi-Chun; Hubbard Robert D; Zhang Qian; Grudzien Meagan M; Soni Niru B; Johnson Eric F; Sheppard George S; Donawho Cherrie; Buchanan Fritz G; Davidsen Steven K; Bell Randy L; Wang Jieyi
Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.
BMC cancer 2009;9():314.
2008: Jasinghe Viraj J; Xie Zhigang; Zhou Jianbiao; Khng Jiaying; Poon Lai-Fong; Senthilnathan Palaniyandi; Glaser Keith B; Albert Daniel H; Davidsen Steven K; Chen Chien-Shing
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.
Journal of hepatology 2008;49(6):985-97.
2008: Wilsbacher Julie L; Zhang Qian; Tucker Lora A; Hubbard Robert D; Sheppard George S; Bamaung Nwe Y; Fidanze Steve D; Wang Gary T; Hu Xiaoming; Davidsen Steven K; Bell Randy L; Wang Jieyi
Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
The Journal of biological chemistry 2008;283(35):23721-30.
2008: Zhou Jianbiao; Khng Jiaying; Jasinghe Viraj J; Bi Chonglei; Neo Chiew Hoon Serene; Pan Mengfei; Poon Lai Fong; Xie Zhigang; Yu Hanry; Yeoh Allen Eng-Juh; Lu Yi; Glaser Keith B; Albert Daniel H; Davidsen Steven K; Chen Chien-Shing
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor.
Leukemia research 2008;32(7):1091-100.
2008: Tucker L A; Zhang Q; Sheppard G S; Lou P; Jiang F; McKeegan E; Lesniewski R; Davidsen S K; Bell R L; Wang J
Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation.
Oncogene 2008;27(28):3967-76.
2008: Gracias Vijaya; Ji Zhiqin; Akritopoulou-Zanze Irini; Abad-Zapatero Cele; Huth Jeffrey R; Song Danying; Hajduk Philip J; Johnson Eric F; Glaser Keith B; Marcotte Patrick A; Pease Lori; Soni Nirupama B; Stewart Kent D; Davidsen Steven K; Michaelides Michael R; Djuric Stevan W
Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(8):2691-5.
2008: Ji Zhiqin; Ahmed Asma A; Albert Daniel H; Bouska Jennifer J; Bousquet Peter F; Cunha George A; Diaz Gilbert; Glaser Keith B; Guo Jun; Harris Christopher M; Li Junling; Marcotte Patrick A; Moskey Maria D; Oie Tetsuro; Pease Lori; Soni Nirupama B; Stewart Kent D; Davidsen Steven K; Michaelides Michael R
3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.
Journal of medicinal chemistry 2008;51(5):1231-41.
2008: Dai Yujia; Hartandi Kresna; Soni Niru B; Pease Lori J; Reuter David R; Olson Amanda M; Osterling Donald J; Doktor Stella Z; Albert Daniel H; Bouska Jennifer J; Glaser Keith B; Marcotte Patrick A; Stewart Kent D; Davidsen Steven K; Michaelides Michael R
Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(1):386-90.
2008: Zhou J; Pan M; Xie Z; Loh S-L; Bi C; Tai Y-C; Lilly M; Lim Y-P; Han J-H; Glaser K B; Albert D H; Davidsen S K; Chen C-S
Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(1):138-46.
2007: Hubbard Robert D; Bamaung Nwe Y; Palazzo Fabio; Zhang Qian; Kovar Peter; Osterling Donald J; Hu Xiaoming; Wilsbacher Julie L; Johnson Eric F; Bouska Jennifer; Wang Jieyi; Bell Randy L; Davidsen Steven K; Sheppard George S
Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR).
Bioorganic & medicinal chemistry letters 2007;17(19):5406-9.
2007: Dinges Jürgen; Albert Daniel H; Arnold Lee D; Ashworth Kimba L; Akritopoulou-Zanze Irini; Bousquet Peter F; Bouska Jennifer J; Cunha George A; Davidsen Steven K; Diaz Gilbert J; Djuric Stevan W; Gasiecki Alan F; Gintant Gary A; Gracias Vijaya J; Harris Christopher M; Houseman Kathryn A; Hutchins Charles W; Johnson Eric F; Li Hu; Marcotte Patrick A; Martin Ruth L; Michaelides Michael R; Nyein Michelle; Sowin Thomas J; Su Zhi; Tapang Paul H; Xia Zhiren; Zhang Henry Q
1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Journal of medicinal chemistry 2007;50(9):2011-29.
2007: Dai Yujia; Hartandi Kresna; Ji Zhiqin; Ahmed Asma A; Albert Daniel H; Bauch Joy L; Bouska Jennifer J; Bousquet Peter F; Cunha George A; Glaser Keith B; Harris Christopher M; Hickman Dean; Guo Jun; Li Junling; Marcotte Patrick A; Marsh Kennan C; Moskey Maria D; Martin Ruth L; Olson Amanda M; Osterling Donald J; Pease Lori J; Soni Niru B; Stewart Kent D; Stoll Vincent S; Tapang Paul; Reuter David R; Davidsen Steven K; Michaelides Michael R
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Journal of medicinal chemistry 2007;50(7):1584-97.
2007: Shankar Deepa B; Li Junling; Tapang Paul; Owen McCall J; Pease Lori J; Dai Yujia; Wei Ru-Qi; Albert Daniel H; Bouska Jennifer J; Osterling Donald J; Guo Jun; Marcotte Patrick A; Johnson Eric F; Soni Niru; Hartandi Kresna; Michaelides Michael R; Davidsen Steven K; Priceman Saul J; Chang Jenny C; Rhodes Katrin; Shah Neil; Moore Theodore B; Sakamoto Kathleen M; Glaser Keith B
ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
Blood 2007;109(8):3400-8.
2007: Heyman H Robin; Frey Robin R; Bousquet Peter F; Cunha George A; Moskey Maria D; Ahmed Asma A; Soni Niru B; Marcotte Patrick A; Pease Lori J; Glaser Keith B; Yates Melinda; Bouska Jennifer J; Albert Daniel H; Black-Schaefer Candace L; Dandliker Peter J; Stewart Kent D; Rafferty Paul; Davidsen Steven K; Michaelides Michael R; Curtin Michael L
Thienopyridine urea inhibitors of KDR kinase.
Bioorganic & medicinal chemistry letters 2007;17(5):1246-9.
2006: Dinges Jürgen; Ashworth Kimba L; Akritopoulou-Zanze Irini; Arnold Lee D; Baumeister Steven A; Bousquet Peter F; Cunha George A; Davidsen Steven K; Djuric Stevan W; Gracias Vijaya J; Michaelides Michael R; Rafferty Paul; Sowin Thomas J; Stewart Kent D; Xia Zhiren; Zhang Henry Q
1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.
Bioorganic & medicinal chemistry letters 2006;16(16):4266-71.
2006: Ji Zhiqin; Ahmed Asma A; Albert Daniel H; Bouska Jennifer J; Bousquet Peter F; Cunha George A; Glaser Keith B; Guo Jun; Li Junling; Marcotte Patrick A; Moskey Maria D; Pease Lori J; Stewart Kent D; Yates Melinda; Davidsen Steven K; Michaelides Michael R
Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
Bioorganic & medicinal chemistry letters 2006;16(16):4326-30.
2006: Sheppard George S; Wang Jieyi; Kawai Megumi; Fidanze Steve D; BaMaung Nwe Y; Erickson Scott A; Barnes David M; Tedrow Jason S; Kolaczkowski Lawrence; Vasudevan Anil; Park David C; Wang Gary T; Sanders William J; Mantei Robert A; Palazzo Fabio; Tucker-Garcia Lora; Lou Pingping; Zhang Qian; Park Chang H; Kim Ki H; Petros Andrew; Olejniczak Edward; Nettesheim David; Hajduk Phillip; Henkin Jack; Lesniewski Richard; Davidsen Steven K; Bell Randy L
Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding.
Journal of medicinal chemistry 2006;49(13):3832-49.
2006: Guo Jun; Marcotte Patrick A; McCall J Owen; Dai Yujia; Pease Lori J; Michaelides Michael R; Davidsen Steven K; Glaser Keith B
Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Molecular cancer therapeutics 2006;5(4):1007-13.
2006: Albert Daniel H; Tapang Paul; Magoc Terrance J; Pease Lori J; Reuter David R; Wei Ru-Qi; Li Junling; Guo Jun; Bousquet Peter F; Ghoreishi-Haack Nayereh S; Wang Baole; Bukofzer Gail T; Wang Yi-Chun; Stavropoulos Jason A; Hartandi Kresna; Niquette Amanda L; Soni Nirupama; Johnson Eric F; McCall J Owen; Bouska Jennifer J; Luo Yanping; Donawho Cherrie K; Dai Yujia; Marcotte Patrick A; Glaser Keith B; Michaelides Michael R; Davidsen Steven K
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Molecular cancer therapeutics 2006;5(4):995-1006.
2005: Dai Yujia; Guo Yan; Frey Robin R; Ji Zhiqin; Curtin Michael L; Ahmed Asma A; Albert Daniel H; Arnold Lee; Arries Shannon S; Barlozzari Teresa; Bauch Joy L; Bouska Jennifer J; Bousquet Peter F; Cunha George A; Glaser Keith B; Guo Jun; Li Junling; Marcotte Patrick A; Marsh Kennan C; Moskey Maria D; Pease Lori J; Stewart Kent D; Stoll Vincent S; Tapang Paul; Wishart Neil; Davidsen Steven K; Michaelides Michael R
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Journal of medicinal chemistry 2005;48(19):6066-83.
2004: Glaser K B; Li J; Pease L J; Staver M J; Marcotte P A; Guo J; Frey R R; Garland R B; Heyman H R; Wada C K; Vasudevan A; Michaelides M R; Davidsen S K; Curtin M L
Differential protein acetylation induced by novel histone deacetylase inhibitors.
Biochemical and biophysical research communications 2004;325(3):683-90.
2004: Curtin Michael L; Frey Robin R; Heyman H Robin; Sarris Kathy A; Steinman Douglas H; Holmes James H; Bousquet Peter F; Cunha George A; Moskey Maria D; Ahmed Asma A; Pease Lori J; Glaser Keith B; Stewart Kent D; Davidsen Steven K; Michaelides Michael R
Isoindolinone ureas: a novel class of KDR kinase inhibitors.
Bioorganic & medicinal chemistry letters 2004;14(17):4505-9.
2004: Li Junling; Staver Michael J; Curtin Michael L; Holms James H; Frey Robin R; Edalji Rohinton; Smith Richard; Michaelides Mike R; Davidsen Steven K; Glaser Keith B
Expression and functional characterization of recombinant human HDAC1 and HDAC3.
Life sciences 2004;74(22):2693-705.
2003: Vasudevan Anil; Ji Zhiqin; Frey Robin R; Wada Carol K; Steinman Douglas; Heyman H Robin; Guo Yan; Curtin Michael L; Guo Jun; Li Junling; Pease Lori; Glaser Keith B; Marcotte Patrick A; Bouska Jennifer J; Davidsen Steven K; Michaelides Michael R
Heterocyclic ketones as inhibitors of histone deacetylase.
Bioorganic & medicinal chemistry letters 2003;13(22):3909-13.
2003: Dai Yujia; Guo Yan; Curtin Michael L; Li Junling; Pease Lori J; Guo Jun; Marcotte Patrick A; Glaser Keith B; Davidsen Steven K; Michaelides Michael R
A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.
Bioorganic & medicinal chemistry letters 2003;13(21):3817-20.
2003: Glaser Keith B; Li Junling; Staver Michael J; Wei Ru-Qi; Albert Daniel H; Davidsen Steven K
Role of class I and class II histone deacetylases in carcinoma cells using siRNA.
Biochemical and biophysical research communications 2003;310(2):529-36.
2003: Wada Carol K; Frey Robin R; Ji Zhiqin; Curtin Michael L; Garland Robert B; Holms James H; Li Junling; Pease Lori J; Guo Jun; Glaser Keith B; Marcotte Patrick A; Richardson Paul L; Murphy Shannon S; Bouska Jennifer J; Tapang Paul; Magoc Terrance J; Albert Daniel H; Davidsen Steven K; Michaelides Michael R
Alpha-keto amides as inhibitors of histone deacetylase.
Bioorganic & medicinal chemistry letters 2003;13(19):3331-5.
2003: Dai Yujia; Guo Yan; Guo Jun; Pease Lori J; Li Junling; Marcotte Patrick A; Glaser Keith B; Tapang Paul; Albert Daniel H; Richardson Paul L; Davidsen Steven K; Michaelides Michael R
Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
Bioorganic & medicinal chemistry letters 2003;13(11):1897-901.
2003: Glaser Keith B; Staver Michael J; Waring Jeffrey F; Stender Joshua; Ulrich Roger G; Davidsen Steven K
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.
Molecular cancer therapeutics 2003;2(2):151-63.
2002: Hajduk Philip J; Shuker Suzanne B; Nettesheim David G; Craig Richard; Augeri David J; Betebenner David; Albert Daniel H; Guo Yan; Meadows Robert P; Xu Lianhong; Michaelides Michael; Davidsen Steven K; Fesik Stephen W
NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.
Journal of medicinal chemistry 2002;45(26):5628-39.
2002: Frey Robin R; Wada Carol K; Garland Robert B; Curtin Michael L; Michaelides Michael R; Li Junling; Pease Lori J; Glaser Keith B; Marcotte Patrick A; Bouska Jennifer J; Murphy Shannon S; Davidsen Steven K
Trifluoromethyl ketones as inhibitors of histone deacetylase.
Bioorganic & medicinal chemistry letters 2002;12(23):3443-7.
2002: Curtin Michael L; Garland Robert B; Heyman H Robin; Frey Robin R; Michaelides Michael R; Li Junling; Pease Lori J; Glaser Keith B; Marcotte Patrick A; Davidsen Steven K
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
Bioorganic & medicinal chemistry letters 2002;12(20):2919-23.
2002: Wada Carol K; Holms James H; Curtin Michael L; Dai Yujia; Florjancic Alan S; Garland Robert B; Guo Yan; Heyman H Robin; Stacey Jamie R; Steinman Douglas H; Albert Daniel H; Bouska Jennifer J; Elmore Ildiko N; Goodfellow Carole L; Marcotte Patrick A; Tapang Paul; Morgan Douglas W; Michaelides Michael R; Davidsen Steven K
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
Journal of medicinal chemistry 2002;45(1):219-32.
2001: Gum R J; Hickman D; Fagerland J A; Heindel M A; Gagne G D; Schmidt J M; Michaelides M R; Davidsen S K; Ulrich R G
Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1).
Biochemical pharmacology 2001;62(12):1661-73.
2001: Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
Bioorganic & medicinal chemistry letters 2001;11(22):2907-10.
2001: Curtin M L; Florjancic A S; Heyman H R; Michaelides M R; Garland R B; Holms J H; Steinman D H; Dellaria J F; Gong J; Wada C K; Guo Y; Elmore I B; Tapang P; Albert D H; Magoc T J; Marcotte P A; Bouska J J; Goodfellow C L; Bauch J L; Marsh K C; Morgan D W; Davidsen S K
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
Bioorganic & medicinal chemistry letters 2001;11(12):1557-60.
2001: Michaelides M R; Dellaria J F; Gong J; Holms J H; Bouska J J; Stacey J; Wada C K; Heyman H R; Curtin M L; Guo Y; Goodfellow C L; Elmore I B; Albert D H; Magoc T J; Marcotte P A; Morgan D W; Davidsen S K
Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.
Bioorganic & medicinal chemistry letters 2001;11(12):1553-6.
2000: Rabbani S A; Harakidas P; Guo Y; Steinman D; Davidsen S K; Morgan D W
Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo.
International journal of cancer. Journal international du cancer 2000;87(2):276-82.
1999: Marcotte P A; Elmore I N; Guan Z; Magoc T J; Albert D H; Morgand D W; Curtin M L; Garland R B; Guo Y; Heyman H R; Holms J H; Sheppard G S; Steinman D H; Wada C K; Davidsen S K
Evaluation of the inhibition of other metalloproteinases by matrix metalloproteinase inhibitors.
Journal of enzyme inhibition 1999;14(6):425-35.
1998: Sheppard G S; Florjancic A S; Giesler J R; Xu L; Guo Y; Davidsen S K; Marcotte P A; Elmore I; Albert D H; Magoc T J; Bouska J J; Goodfellow C L; Morgan D W; Summers J B
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
Bioorganic & medicinal chemistry letters 1998;8(22):3251-6.
1998: Steinman D H; Curtin M L; Garland R B; Davidsen S K; Heyman H R; Holms J H; Albert D H; Magoc T J; Nagy I B; Marcotte P A; Li J; Morgan D W; Hutchins C; Summers J B
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.
Bioorganic & medicinal chemistry letters 1998;8(16):2087-92.
1998: Curtin M L; Garland R B; Davidsen S K; Marcotte P A; Albert D H; Magoc T J; Hutchins C
Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.
Bioorganic & medicinal chemistry letters 1998;8(12):1443-8.
1998: Curtin M L; Davidsen S K; Heyman H R; Garland R B; Sheppard G S; Florjancic A S; Xu L; Carrera G M; Steinman D H; Trautmann J A; Albert D H; Magoc T J; Tapang P; Rhein D A; Conway R G; Luo G; Denissen J F; Marsh K C; Morgan D W; Summers J B
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
Journal of medicinal chemistry 1998;41(1):74-95.
1998: Albert D H; Malo P E; Tapang P; Shaughnessy T K; Morgan D W; Wegner C D; Curtin M L; Sheppard G S; Xu L; Davidsen S K; Summers J B; Carter G W
The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.
The Journal of pharmacology and experimental therapeutics 1998;284(1):83-8.
1997: Albert D H; Tapang P; Morgan D W; Curtin M L; Sheppard G S; Davidsen S K; Summers J B; Carter G W
ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway rats.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1997;46 Suppl 2():S133-4.
1997: Albert D H; Magoc T J; Tapang P; Luo G; Morgan D W; Curtin M; Sheppard G S; Xu L; Heyman H R; Davidsen S K; Summers J B; Carter G W
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.
European journal of pharmacology 1997;325(1):69-80.
1996: Albert D H; Luo G; Magoc T J; Tapang P; Holms J H; Davidsen S K; Summers J B; Carter G W
ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
Shock (Augusta, Ga.) 1996;6(2):112-7.
1996: Albert D H; Conway R G; Magoc T J; Tapang P; Rhein D A; Luo G; Holms J H; Davidsen S K; Summers J B; Carter G W
Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.
The Journal of pharmacology and experimental therapeutics 1996;277(3):1595-606.
1995: Summers J B; Albert D H; Davidsen S K; Conway R G; Holms J H; Magoc T J; Luo G; Tapang P; Rhein D A; Carter G W
ABT-299, a potent antagonist of platelet activating factor.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():475-7.
1994: Davidsen S K; Summers J B; Albert D H; Holms J H; Heyman H R; Magoc T J; Conway R G; Rhein D A; Carter G W
N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist.
Journal of medicinal chemistry 1994;37(26):4423-9.
1994: Sheppard G S; Pireh D; Carrera G M; Bures M G; Heyman H R; Steinman D H; Davidsen S K; Phillips J G; Guinn D E; May P D
3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists.
Journal of medicinal chemistry 1994;37(13):2011-32.
1992: Devine E M; Buko A M; Cepa S P; Davidsen S K; Holleman W H; Marselle C A; Opgenorth T J; Rockway T W; von Geldern T W
HPLC and PDMS analysis of cleavage products aid in the design of small, stable ANP analogues.
International journal of peptide and protein research 1992;40(6):532-7.
1992: von Geldern T W; Rockway T W; Davidsen S K; Budzik G P; Bush E N; Chu-Moyer M Y; Devine E M; Holleman W H; Johnson M C; Lucas S D
Small atrial natriuretic peptide analogues: design, synthesis, and structural requirements for guanylate cyclase activation.
Journal of medicinal chemistry 1992;35(5):808-16.
1990: Opgenorth T J; Budzik G P; Mollison K W; Davidsen S K; Holst M R; Holleman W H
Atrial peptides induce mast cell histamine release.
Peptides 1990;11(5):1003-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Steven Davidsen

Research Profile (preview)

Concepts & Ideas

Living Beings

Chemicals & Drugs

Procedures

Anatomy

Disorders

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Steven Davidsen (preview)

All Publications